Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
| dc.contributor.author | Swords, RT | |
| dc.contributor.author | Watts, J | |
| dc.contributor.author | Erba, HP | |
| dc.contributor.author | Altman, JK | |
| dc.contributor.author | Maris, M | |
| dc.contributor.author | Anwer, F | |
| dc.contributor.author | Hua, Z | |
| dc.contributor.author | Stein, H | |
| dc.contributor.author | Faessel, H | |
| dc.contributor.author | Sedarati, F | |
| dc.contributor.author | Dezube, BJ | |
| dc.contributor.author | Giles, FJ | |
| dc.contributor.author | Medeiros, BC | |
| dc.contributor.author | DeAngelo, DJ | |
| dc.date.accessioned | 2019-12-01T17:51:13Z | |
| dc.date.available | 2019-12-01T17:51:13Z | |
| dc.date.issued | 2017-02-03 | |
| dc.date.updated | 2019-12-01T17:51:11Z | |
| dc.identifier | bcj20171 | |
| dc.identifier.issn | 2044-5385 | |
| dc.identifier.issn | 2044-5385 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.relation.ispartof | Blood cancer journal | |
| dc.relation.isversionof | 10.1038/bcj.2017.1 | |
| dc.subject | Humans | |
| dc.subject | Myelodysplastic Syndromes | |
| dc.subject | Cyclopentanes | |
| dc.subject | Pyrimidines | |
| dc.subject | Enzyme Inhibitors | |
| dc.subject | Maximum Tolerated Dose | |
| dc.subject | Adult | |
| dc.subject | Aged | |
| dc.subject | Aged, 80 and over | |
| dc.subject | Middle Aged | |
| dc.subject | Female | |
| dc.subject | Male | |
| dc.subject | Leukemia, Myeloid, Acute | |
| dc.subject | Young Adult | |
| dc.subject | NEDD8 Protein | |
| dc.title | Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Erba, HP|0000-0003-1093-2189 | |
| pubs.begin-page | e520 | |
| pubs.issue | 2 | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | Duke Cancer Institute | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.publication-status | Published | |
| pubs.volume | 7 |
Files
Original bundle
- Name:
- Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.pdf
- Size:
- 476.52 KB
- Format:
- Adobe Portable Document Format